Adverum Biotechnologies

Adverum Biotechnologies is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing therapeutic benefit to patients dealing with chronic or debilitating disease. We are leveraging our next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.

Company Growth (employees)
Type
Public
HQ
Menlo Park, US
Founded
2006
Size (employees)
61 (est)+13%
Adverum Biotechnologies was founded in 2006 and is headquartered in Menlo Park, US

Key People at Adverum Biotechnologies

Linda C. Bain

Linda C. Bain

CFO
Mark S. Blumenkranz

Mark S. Blumenkranz

Founder & Director
Mehdi Gasmi

Mehdi Gasmi

Vice President, Pharmaceutical Development
Steven D. Schwartz

Steven D. Schwartz

Founder & Director
Hans Hull

Hans Hull

Vice President, Legal and Corporate Development
Mitchell H. Finer

Mitchell H. Finer

Founder & Senior Consultant

Adverum Biotechnologies Office Locations

Adverum Biotechnologies has offices in Menlo Park, Philadelphia
Menlo Park, US (HQ)
1035 O'Brien Dr

Adverum Biotechnologies Metrics

Adverum Biotechnologies Financial Metrics

Net income (2016)

($113.7 m)

Cash (31-Dec-2016)

$222.2 m
Adverum Biotechnologies's revenue was reported to be $2.3 m in FY, 2015
FY, 2014FY, 2015FY, 2016

Revenue

$572 k$2.3 m

Revenue growth, %

305%

R&D expense

$17 m$25.5 m$31.7 m

General and administrative expense

$8 m$22.1 m$24.4 m

Operating expense total

$25 m$50.1 m$116.7 m

EBIT

($24.4 m)($47.8 m)($115.3 m)

EBIT margin, %

(4266%)(2062%)

Interest expense

($18 k)($18 k)($18 k)

Income tax expense

$775 k

Net Income

($25.4 m)($47.5 m)($113.7 m)
FY, 2014FY, 2015FY, 2016

Cash

$159.4 m$221.3 m$222.2 m

Accounts Receivable

$551.6 m

Inventories

$210.3 m

Current Assets

$160.3 m$261 m$225.3 m

PP&E

$1.1 m$3.2 m$4.2 m

Total Assets

$161.9 m$264.3 m$234.6 m

Accounts Payable

$37.1 m$391.2 m

Current Liabilities

$5.5 m$6.6 m$9.9 m

Additional Paid-in Capital

$186.2 m$336.8 m$413.5 m

Retained Earnings

($36.7 m)($84.2 m)($197.9 m)

Total Equity

$149.5 m$252.6 m$215.6 m

Financial Leverage

1.1 x1 x1.1 x
FY, 2014FY, 2015FY, 2016

Net Income

($25.4 m)($47.5 m)($113.7 m)

Depreciation and Amortization

$162 k$1.6 m

Accounts Receivable

($44 k)$58 k

Accounts Payable

$18.2 m($15.5 m)

Cash From Operating Activities

($5.6 m)($38.4 m)

Purchases of PP&E

($943 k)($2.4 m)

Cash From Investing Activities

($943 k)$38.8 m

Cash From Financing Activities

$165.4 m$556 k

Adverum Biotechnologies Job Categories

Adverum Biotechnologies Company Life

You may also be interested in